Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Cancer Nsclc Equipment Supplied In Europe
11 equipment items found
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our product is a new-generation CAP6 that shows great promise as a highly effective treatment for lung cancer (NSCLC). Lung cancer is one of the most widely prevalent cancers, and one of the most difficult to treat. Eighty-one percent of patients treated for lung cancer die within five ...
by:F. Hoffmann-La Roche Ltd. based inBasel, SWITZERLAND
Alecensa is a highly selective, central nervous system-active, oral medicine used for the treatment of people with non-small cell lung cancer (NSCLC) whose tumours are identified as anaplastic lymphoma kinase (ALK)-positive. Alecensa is a tyrosine kinase inhibitor that targets ALK fusion proteins, preventing signalling within cancer cells to ...
by:Genmab A/S based inCopenhagen V, DENMARK
Amivantamab is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform. The two antibody libraries used to produce amivantamab were both generated by Genmab. The antibody pair used to ...
Manufactured by:ViennaLab Diagnostics GmbH based inVienna, AUSTRIA
NSCLC comprises approximately 85% of all lung cancers. Tumor specimens from patients should be tested for the presence of EGFR mutations prior to TKI treatment. The EGFR XL StripAssay® and EGFR T790M RealFast™ Assay are designed to assist clinicians in the stratification of patients considered for TKI ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several tumour types including synovial sarcomas, oesophageal, liver, gastric, prostate and lung ...
Manufactured by:Stilla Technologies based inVillejuif, FRANCE
Get ready-to-use, fully-validated panels for the detection and quantification of nucleic acids. Crystal Digital PCR™ kits allows researchers to detect and quantify nucleic acids with ready-to-use, pre-designed assays for fully-validated target panels. These digital PCR panel kits are specially developed by Stilla Technologies and its partners ID Solutions. For fully-customizable kits and/or ...
Manufactured by:Virasoft Inc. based inSarıyer, TURKEY
Programmed cell death protein 1 (PD-1; also called CD279) is one of the co-inhibitory receptors that is expressed on the surface of antigen-stimulated T cells [1]. Normally, PD-L1 expression can be detected on hematopoietic cells including T cells, B cells, macrophages, dendritic cells, mast cells and healthy tissue cells. But PD-L1 can be expressed by tumor cells and tumor stroma. Interaction ...
Manufactured by:ViennaLab Diagnostics GmbH based inVienna, AUSTRIA
A reliable tool to personalize therapy of lung cancer patients with acquired TKI-resistance mutation T790M in the EGFR ...
Manufactured by:INTERmedic Arfran based inBarcelona, SPAIN
INTERmedic, worldwide leader in photodynamic therapy for pulmonology (lung cancer), gastroenterology (Barrett’s esophagus, esophageal cancer), urology (prostate cancer) among others, presents Multidiode™ PDT, an innovative technology to treat dermatological pathologies such as basal cell carcinoma, cholangiocarcinoma or hidradenitis ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell ...
by:Pure Biologics SA based inWroclaw, POLAND
In cancer, a balance between immune system effector and regulatory cells becomes disturbed. Regulatory T cells inhibit the activity of effector cells, including NK cells, a process known as immunosuppression. The PB003 (PureActivator) project embraces a novel approach, aiming to develop a drug based on a bimodal fusion protein, which synergistically activates NK cells and minimizes ...